A mitochondria-derived peptide encoded within mitochondrial DNA — discovered only in 2015. Circulates in human blood, increases during exercise, and declines with age. Studied for AMPK activation, insulin sensitivity, and its association with exceptional longevity in centenarian populations.
Also known as: Mitochondrial Open Reading Frame of 12S rRNA-c, mtDNA-encoded peptide
MOTS-C is not just a research compound — it is a molecule your body has always produced. It circulates in your blood at measurable levels from youth and serves as a real-time signal of your mitochondria's health. Two things researchers have found particularly compelling: it rises significantly during exercise (suggesting a role in the beneficial effects of physical activity) and falls with age. Most strikingly, people who live to 100+ years have been found to carry distinct genetic variants of MOTS-C.
MOTS-C plasma concentration across age groups and exercise response — Nature Communications, 2020
Cell Reports, 2020 ›MOTS-C's mechanism is unusual — it works by blocking a metabolic pathway, which paradoxically activates a more powerful one. Understanding this chain reaction explains why its effects span insulin sensitivity, fat metabolism, and cellular stress response simultaneously.
| Year | Finding | Observed Effect | Source |
|---|---|---|---|
| 2015 | Discovery — AMPK and Insulin | 78% insulin improvement, AMPK activation | Cell Metabolism, 2015 |
| 2020 | Exercise response | Rises during exercise, improves aged performance | Nature Comms, 2020 |
| 2020 | Centenarian variants | Distinct variants in 100+ populations | Cell Reports, 2020 |
| Ongoing | Human plasma aging | Significant age-related decline confirmed | Multiple studies |
| Active | Human clinical research | Ongoing investigation | Current research |
MOTS-C was discovered in 2015 — it is a young research area. Safety data comes from preclinical studies only. No human clinical trials have been published yet.
As a recently discovered peptide, MOTS-C's safety record is limited to preclinical research. Animal studies have not documented adverse effects. However, the absence of human clinical data means human safety has not been formally evaluated — this is standard for any compound at the preclinical research stage.
Research Use Only. MOTS-C research is at an early preclinical stage. No completed human clinical trials have been published. Sold for research purposes only. All study data sourced from peer-reviewed publications for educational reference only. By purchasing you confirm you are a qualified researcher. View full policy.